Metabolic activity of gut bacteria can either promote or inhibit function of CAR T cells in cancer therapy

Дата публикации: 28-09-2026 20:00:05

Immunotherapies, especially CAR T-cell therapy, have fundamentally changed cancer treatment in recent years, particularly for certain forms of leukemia and lymphoma. Yet not all tumors respond equally well, and the reasons for this remain incompletely understood. A new multicenter study by the Leibniz Institute for Immunotherapy collaboration group, Innate Immune Sensing in Cancer and Transplantation, now shows that it is not only the composition of the gut microbiota that determines the success of CAR T-cell therapy, but above all its metabolic products.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	'Plug-and-play' CAR T technology adapts as cancer changes	0	8.18	22-09-2026
2	Cancer biologists bring in the B-cell reinforcements for immunotherapy	0	8.93	17-09-2026
3	Study identifies potential RAS inhibitor-immunotherapy strategy for pancreatic cancer	0	7.48	23-09-2026
4	Making invisible cancers visible: A new route to turn 'cold' tumors 'hot'	0	7.83	17-09-2026
5	A blood-based approach could enable personalized immunotherapy without the need for a tumor biopsy	0	10.91	29-09-2026
6	Activated donor immune cells may prevent severe complication after allogeneic stem cell transplantation	0	8.94	20-09-2026
7	Speaker: CAR T-cell trial deaths add ‘sobriety’ to discussions with autoimmune patients	0	9.17	28-09-2026
8	Protein modification network plays vital role in cancer development	0	6.81	24-09-2026
9	Liver, gut bacteria alter food molecules, influence body’s biological activity	0	5.94	23-09-2026
10	High-fat diets suppress enzyme in immune cells, promoting fat tissue inflammation in mice	0	11.54	23-09-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 6.96. Источник: medicalxpress.com.